A Cyclen‐Based Tetraphosphinate Chelator for the Preparation of Radiolabeled Tetrameric Bioconjugates. Issue 24 (23rd April 2013)

• Record Type: Journal Article
• Authors: Šimeček, Jakub; Hermann, Petr; Havlíčková, Jana; Herdtweck, Eberhardt; Kapp, Tobias G.; Engelbogen, Nils; Kessler, Horst; Wester, Hans‐Jürgen; Notni, Johannes
• Is Part Of: Chemistry. Volume 19:Issue 24(2013)
• Page Start: 7748
• Page End: 7757
• Publication Date: 2013-04-23
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1002/chem.201300338
• Languages: English
• ISSNs: 0947-6539

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>The cyclen‐based tetraphosphinate chelator 1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetrakis[methylene(2‐carboxyethyl)phosphinic acid] (DOTPI) comprises four additional carboxylic acid moieties for bioconjugation. The thermodynamic stability constants (log<italic>K</italic><sub>ML</sub>) of metal complexes, as determined by potentiometry, were 23.11 for Cu<sup>II</sup>, 20.0 for Lu<sup>III</sup>, 19.6 for Y<sup>III</sup>, and 21.0 for Gd<sup>III</sup>. DOTPI was functionalized with four cyclo(Arg‐Gly‐Asp‐<sc>D</sc>‐Phe‐Lys) (RGD) peptides through polyethylene glycol (PEG<sub>4</sub>) linkers. The resulting tetrameric conjugate DOTPI(RGD)<sub>4</sub> was radiolabeled with <sup>177</sup>Lu and <sup>64</sup>Cu and showed improved labeling efficiency compared with 1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetraacetic acid (DOTA). The labeled compounds were fully stable in transchelation challenges against trisodium diethylenetriaminepentaacetate (DTPA) and disodium ethylenediaminetetraacetic acid (ETDA), in phosphate buffered saline (PBS), and human plasma. Integrin α<sub>v</sub>β<sub>3</sub> affinities of the non‐radioactive Lu<sup>III</sup> and Cu<sup>II</sup> complexes of DOTPI(RGD)<sub>4</sub> were 18 times higher (both IC<sub>50</sub> about 70 picomolar) than that of the c(RGDfK) peptide (IC<sub>50</sub>=1.3 nanomolar). Facile access to tetrameric conjugates and the possibility of radiolabeling with therapeutic and diagnostic radionuclides render DOTPI suitable for application in peptide receptor radionuclide imaging (PRRI) and therapy (PRRT).</p> </abstract>